A323990 Stock Overview
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Vaxcell-Bio Therapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩16,050.00 |
| 52 Week High | ₩47,416.67 |
| 52 Week Low | ₩14,350.00 |
| Beta | 3.73 |
| 1 Month Change | -28.82% |
| 3 Month Change | -16.75% |
| 1 Year Change | -55.00% |
| 3 Year Change | -79.47% |
| 5 Year Change | n/a |
| Change since IPO | 80.85% |
Recent News & Updates
Shareholder Returns
| A323990 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.4% | 5.4% | 3.4% |
| 1Y | -55.0% | 6.7% | 7.1% |
Price Volatility
| A323990 volatility | |
|---|---|
| A323990 Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.vaxcell-bio.com |
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.
Vaxcell-Bio Therapeutics Co., Ltd. Fundamentals Summary
| A323990 fundamental statistics | |
|---|---|
| Market cap | ₩369.04b |
| Earnings (TTM) | -₩10.27b |
| Revenue (TTM) | ₩13.72m |
Over9,999x
P/S Ratio-35.9x
P/E RatioIs A323990 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A323990 income statement (TTM) | |
|---|---|
| Revenue | ₩13.72m |
| Cost of Revenue | ₩10.44m |
| Gross Profit | ₩3.28m |
| Other Expenses | ₩10.28b |
| Earnings | -₩10.27b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -446.83 |
| Gross Margin | 23.90% |
| Net Profit Margin | -74,865.84% |
| Debt/Equity Ratio | 0% |
How did A323990 perform over the long term?
See historical performance and comparison